<template>
	<div id="app" class="p_4 texture_light">
		<article class="bg_white shadow_1 br-t_3 br_solid br_secondary relative">
			<a class="absolute t_0 r_0 bg_secondary c_white-4 h:c_white p_2 font_n2 p-x_3">
				<i class="fa fa-expand font_n1 lh_1"></i>
			</a>
			<header class="m-t_3 p-b_0 p-t_3 p-x_4 block" id="item-header-0">
				<h2
					class="c_acc font_1 font_slab lh_1 m-t_3 overflow-ellipsis"
				>Recommendations for Anticoagulation for Atrial Fibrillation (AF) in Patients With VHD</h2>
				<div class="font_ui font_n1">
					<span
						class="font_italic c_secondary-3 font_n1 display_none"
					>EID: #1-s2.0-S0735109717360199 ["hl0000348"] Type: table</span>
					<span class="font_bold">Focused Update:</span>Jul 10, 2017
				</div>
			</header>
			<section class="m-b_1 m_0 p-x_4 p-y_2 result-content">
				<div ng-show="showspinner">
					<div class="text_center">
						<i class="fa fa-spinner fa-spin" aria-hidden="true"></i>
					</div>
				</div>
				<div ng-if="data.html" class="retrieve-content ng-scope table">
					<div
						gl-item-container
						label="data.sectiontitle[data.sectiontitle.length-1]"
						doc="data.gltitle"
						data="data.html"
						eid="data.eid"
						id="glcontentid-resultcontent-0"
						containerheight="iscontentheight"
						ng-class="{'gl-contentcollapse':!data.refimage &amp;&amp; iscontentheight>153  &amp;&amp; defaultcollapse==='true'}"
						class="ng-isolate-scope gl-contentcollapse"
					>
						<div id="undtbl2" class="table ng-scope">
							<div
								class="inline-table-caption"
							>Recommendations for Anticoagulation for Atrial Fibrillation (AF) in Patients With VHD</div>
							<div>
								<table id="hl0000351">
									<thead>
										<tr>
											<th id="hl0000358" scope="col" class="table-align-">COR</th>
											<th id="hl0000359" scope="col" class="table-align-">LOE</th>
											<th id="hl0000360" scope="col" class="table-align-">Recommendations</th>
											<th id="hl0000361" scope="col" class="table-align-">Comment/Rationale</th>
										</tr>
									</thead>
									<tbody>
										<tr>
											<td id="hl0000364" class="table-align-">
												<b>I</b>
											</td>
											<td id="hl0000366" class="table-align-">
												<b>B-NR</b>
											</td>
											<td id="hl0000368" class="table-align-" rowspan="2">
												<b>Anticoagulation with a vitamin K antagonist (VKA) is indicated for patients with rheumatic mitral stenosis (MS) and AF</b>
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib34"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>(34</b>
												</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib35"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>35)</b>
												</a>
												<b>.</b>
											</td>
											<td id="hl0000373" class="table-align-" rowspan="2">
												<b>MODIFIED:</b> VKA as opposed to the direct oral anticoagulants (DOACs) are indicated in patients with AF and rheumatic MS to prevent thromboembolic events. The RCTs of DOACs versus VKA have not included patients with MS. The specific recommendation for anticoagulation of patients with MS is contained in a subsection of the topic on anticoagulation (previously in Section 6.2.2).
											</td>
										</tr>
										<tr>
											<td id="hl0000376" class="table-align-" colspan="2">
												See
												<a
													id="hl0000377"
													href="http://jaccjacc.acc.org/Clinical_Document/2017_VHD_Focused_Update_Data_Supplement.pdf"
													target="_blank"
												>Online Data Supplements 3 and 4</a>.
											</td>
										</tr>
										<tr>
											<td id="hl0000379" class="table-align-" colspan="4">
												A retrospective analysis of administrative claims databases (&gt;20,000 DOAC-treated patients) showed no difference in the incidence of stroke or major bleeding in patients with rheumatic and nonrheumatic MS if treated with DOAC versus warfarin
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib35"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>(35)</a>. However, the writing group continues to recommend the use of VKA for patients with rheumatic MS until further evidence emerges on the efficacy of DOAC in this population. (See Section 6.2.2 on Medical Management of Mitral Stenosis in the 2014 guideline.)
											</td>
										</tr>
										<tr>
											<td id="hl0000382" class="table-align-">
												<b>I</b>
											</td>
											<td id="hl0000384" class="table-align-">
												<b>C-LD</b>
											</td>
											<td id="hl0000386" class="table-align-" rowspan="2">
												<b>Anticoagulation is indicated in patients with AF and a CHA</b>
												<sub>2</sub>
												<b>DS</b>
												<sub>2</sub>
												<b>-VASc score of 2 or greater with native aortic valve disease, tricuspid valve disease, or MR</b>
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib36"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>36</b>
												</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib37"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>37</b>
												</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib38"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>38</b>
												</a>
												<b>.</b>
											</td>
											<td id="hl0000395" class="table-align-" rowspan="2">
												<b>NEW:</b> Post hoc subgroup analyses of large RCTs comparing DOAC versus warfarin in patients with AF have analyzed patients with native valve disease other than MS and patients who have undergone cardiac surgery. These analyses consistently demonstrated that the risk of stroke is similar to or higher than that of patients without VHD. Thus, the indication for anticoagulation in these patients should follow GDMT according to the CHA
												<sub>2</sub>DS
												<sub>2</sub>-VASc score
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib35"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>35</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib36"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>36</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib37"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>37</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib38"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>38</a>.
											</td>
										</tr>
										<tr>
											<td id="hl0000401" class="table-align-" colspan="2">
												See
												<a
													id="hl0000402"
													href="http://jaccjacc.acc.org/Clinical_Document/2017_VHD_Focused_Update_Data_Supplement.pdf"
													target="_blank"
												>Online Data Supplements 3 and 4</a>.
											</td>
										</tr>
										<tr>
											<td id="hl0000404" class="table-align-" colspan="4">
												Many patients with VHD have AF, yet these patients were not included in the original studies evaluating the risk of stroke or in the development of the risk schema such as CHADS
												<sub>2</sub> or CHA
												<sub>2</sub>DS
												<sub>2</sub>-VASc
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib39"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>(39</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib40"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>40)</a>. Post hoc subgroup analyses of large RCTs comparing apixaban, rivaroxaban, and dabigatran (DOACs) versus warfarin
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib36"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>36</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib37"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>37</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib38"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>38</a> included patients with VHD, and some included those with bioprosthetic valves or those undergoing valvuloplasty. Although the criteria for nonvalvular AF differed for each trial, patients with significant MS and valve disease requiring an intervention were excluded. There is no clear evidence that the presence of native VHD other than rheumatic MS need be considered in the decision to anticoagulate a patient with AF. On the basis of these findings, the writing group supports the use of anticoagulation in patients with VHD and AF when their CHA
												<sub>2</sub>DS
												<sub>2</sub>-VASc score is 2 or greater. Patients with a bioprosthetic valve or mitral repair and AF are at higher risk for embolic events and should undergo anticoagulation irrespective of the CHA
												<sub>2</sub>DS
												<sub>2</sub>-VASc score.
											</td>
										</tr>
										<tr>
											<td id="hl0000415" class="table-align-">
												<b>IIa</b>
											</td>
											<td id="hl0000417" class="table-align-">
												<b>C-LD</b>
											</td>
											<td id="hl0000419" class="table-align-" rowspan="2">
												<b>
													It is reasonable to use a DOAC as an alternative to a VKA in patients with AF and native aortic valve disease, tricuspid valve disease, or MR and a CHA
													<sub>2</sub>DS
													<sub>2</sub>-VASc score of 2 or greater
												</b>
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib35"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>35</b>
												</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib36"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>36</b>
												</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib37"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>37</b>
												</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib38"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>
													<b>38</b>
												</a>
												<b>.</b>
											</td>
											<td id="hl0000426" class="table-align-" rowspan="2">
												<b>NEW:</b> Several thousand patients with native VHD (exclusive of more than mild rheumatic MS) have been evaluated in RCTs comparing DOACs versus warfarin. Subgroup analyses have demonstrated that DOACs, when compared with warfarin, appear as effective and safe in patients with VHD as in those without VHD.
											</td>
										</tr>
										<tr>
											<td id="hl0000429" class="table-align-" colspan="2">
												See
												<a
													id="hl0000430"
													href="http://jaccjacc.acc.org/Clinical_Document/2017_VHD_Focused_Update_Data_Supplement.pdf"
													target="_blank"
												>Online Data Supplements 3 and 4</a>.
											</td>
										</tr>
										<tr>
											<td id="hl0000432" class="table-align-" colspan="4">
												DOACs appear to be as effective and safe in patients with VHD as they are in those without VHD. In the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonist for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), and RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy) trials, 2,003, 4,808, and 3,950 patients, respectively, had significant VHD
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib36"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>36</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib37"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>37</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib38"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>38</a>. This included MR, mild MS, aortic regurgitation, aortic stenosis (AS), and tricuspid regurgitation. These trials consistently demonstrated at least equivalence to warfarin in reducing stroke and systemic embolism. Retrospective analyses of administrative claims databases (&gt;20,000 DOAC-treated patients) correlate with these findings
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib35"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>(35)</a>. In addition, the rate of intracranial hemorrhage in each trial was lower among patients randomized to dabigatran, rivaroxaban, or apixaban than among those randomized to warfarin, regardless of the presence of VHD
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib36"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>36</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib37"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>37</a>,&nbsp;
												<a
													class="inline-reference"
													data-toggle="modal"
													data-target="#myModal"
													bibid="bib38"
													docid="1-s2.0-S0735109717360199"
													doc-name="Valvular Heart Disease (Focused Update)"
												>38</a>. There is an increased risk of bleeding in patients with VHD versus those without VHD, irrespective of the choice of the anticoagulant.
											</td>
										</tr>
									</tbody>
								</table>
							</div>
						</div>
					</div>
					<!-- ngIf: iscontentheight>153 -->
					<div
						class="m-b_3 m-t_3 ng-scope p-b_3 p-t_0 content-toggle"
						ng-show="data.refimage ==null"
						ng-if="iscontentheight>153"
					>
						<a
							id="contenttoggle-0"
							class="ta-center font_n1 br-b_1 br_0 br_primary br_solid display no-underline"
							ng-click="contenttoggle(defaultcollapse)"
							item-title="Recommendations for Anticoagulation for Atrial Fibrillation (AF) in Patients With VHD"
							doc-name="Valvular Heart Disease (Focused Update)"
						>
							<span class="block m-b_n3 text_center">
								<span class="bg_white p-x_3 font_n1">
									<i
										class="br_secondary-2 br_solid fa m-r_4 p-x_2 p-y_1 fa-angle-down"
										ng-class="{'fa-angle-down': defaultcollapse ==='true', 'fa-angle-up': defaultcollapse !=='true' }"
									></i>
									<span class="font_bold c_acc ng-binding">expand content</span>
								</span>
							</span>
						</a>
					</div>
					<!-- end ngIf: iscontentheight>153 -->
				</div>
				<!-- end ngIf: data.html -->
				<div
					id="myModal"
					class="modal fade"
					role="dialog"
					data-backdrop="true"
					data-animation
					data-keyboard="false"
				>
					<div class="modal-dialog" style="margin:auto; padding-top:5em">
						<!-- Modal content-->
						<div class="modal-content" style="padding:0.75em">
							<div class="modal-header">
								<button type="button" class="close close-x bg_primary c_white p_2" data-dismiss="modal">Ã—</button>
							</div>
							<div id="blibid"></div>
							<br />
							<div class="row">
								<div class="col-md-12 ta-right">
									<button
										type="button"
										id="btncopy"
										class="btn-container"
										ng-click="copytoclipboard('btncopy','blibid')"
										data-toggle="tooltip"
									>Copy</button>
									<button type="button" class="btn-clear" data-dismiss="modal">Close</button>
								</div>
							</div>
						</div>
					</div>
				</div>
			</section>

			<footer class="bg_secondary-5 br-l_0 br-r_0 br_secondary-4 br_solid p-x_4 p-y_2">
				<div class="auto cell font_1 overflow-ellipsis result-title wrap">
					<p style="display:none">
						<span class="font_italic c_secondary-3 font_n1 ng-binding">DOI: 10.1016/j.jacc.2017.03.011</span>
					</p>
					<!-- ngIf: ::data.gltitle -->
					<h4
						ng-if="::data.gltitle"
						class="c_secondary-n2 font_0 font_slab lh_2 ng-binding ng-scope p-b_0 p-t_2"
					>Valvular Heart Disease (Focused Update)</h4>
					<!-- end ngIf: ::data.gltitle -->

					<div class="breadcrumbs">
						<!-- ngIf: ::data.sectiontitleformatted[1] -->
						<span
							class="c_secondary-0 font_n2 p-y_2 ng-binding ng-scope"
							ng-if="::data.sectiontitleformatted[1]"
							ng-bind-html="::data.sectiontitleformatted[1]"
						>
							<span>2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular&nbsp;Heart Disease</span>
						</span>
						<!-- end ngIf: ::data.sectiontitleformatted[1] -->
						<!-- ngIf: ::data.sectiontitleformatted.length-1 > 1 -->
						<span
							class="c_secondary-0 font_n2 p-y_2 ng-binding ng-scope"
							ng-if="::data.sectiontitleformatted.length-1 > 1"
							ng-bind-html="::data.sectiontitleformatted[data.sectiontitleformatted.length-1] "
						>
							<span>Recommendations for Anticoagulation for Atrial Fibrillation (AF) in Patients With VHD</span>
						</span>
					</div>
				</div>
				<div class="font_n2 c_secondary-2 p-y_1"></div>
				<nav class="flex font_n2 p-y_1">
					<div class="flex_shirnk m-r_3 ng-scope" ng-if="::data.jacclink">
						<i class="fa fa-share-square m-r_075"></i>
						<a
							href="http://www.onlinejacc.org/content/70/2/252"
							target="_blank"
							class="link-fulldoc p-y_2 c_primary"
						>
							<span>JACC</span>
						</a>
					</div>
					<div class="flex_shirnk m-r_3 ng-scope" ng-if="::data.pdflink">
						<i class="fa fa-file-pdf-o m-r_075"></i>
						<a
							href="http://www.onlinejacc.org/content/70/2/252.full.pdf"
							target="_blank"
							class="link-pdf p-y_2 c_primary"
						>
							<span>PDF</span>
						</a>
					</div>
					<div class="flex_shirnk ng-scope" ng-if="::data.hub">
						<i class="fa fa-share-alt m-r_075"></i>
						<a
							href="http://www.acc.org/sitecore/content/sites/acc/home/guidelines/hubs/valvular-heart-disease?gl=1"
							target="_blank"
							class="flex_shirnk link-hub p-y_2 c_primary"
						>
							<span>TOOLS</span>
						</a>
					</div>
				</nav>

				<div class="bg_secondary-4 gl-item-footer h:bg_secondary-3 h:c_black h:underline p-y_2 p_3">
					<div class="font_n2">
						<i class="fa fa-quote-right"></i>
						<a
							ng-click="toClipboard(data.citation)"
							id="btn-citation-0"
							data-toggle="tooltip"
							title
							class="m-x_2 c_black"
							data-original-title="Copied to clipboard"
						>cite document</a>
						<span
							ng-bind="::data.citation"
							class="c_secondary-1 ng-binding"
						>J Am Coll Cardiol. 2017 Jul 11;70(2):252-289</span>
					</div>
				</div>
			</footer>
		</article>
	</div>
</template>

<script>
import modal from "./components/modal.vue";

import { mapState, mapMutations, mapActions } from "vuex";

export default {
	name: "app",
	data: function() {
		return {};
	},
	props: {},
	components: {
		modal
	},
	computed: {
		...mapState(["transcript", "creditTypes"])
	},
	methods: {
		...mapMutations([]),
		...mapActions([])
	}
};
</script>

<style>
</style>
